Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2011-01-31 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing FDA approval of a vaccine (Menveo) for a new age indication, details about the vaccine, safety information, and forward-looking statements. There are no financial statements, detailed financial analysis, or comprehensive management discussion of financial results. The document is an announcement of a regulatory approval and related corporate news rather than a financial report or earnings release. It is not a full annual or interim report, nor a call transcript or governance document. Given the nature of the content and the form type (6-K), this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories. The document length (12,580 characters) is substantial, indicating it is not a mere brief announcement but a full regulatory filing. Therefore, the classification is RNS with high confidence.
2011-01-31 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, a foreign private issuer, with the SEC. It contains detailed financial results for the full year 2010 and the fourth quarter of 2010, including net sales, operating income, net income, EPS, and segment performance. It also discusses product approvals, pipeline updates, and strategic commentary from the CEO. The document is lengthy (15,000 characters) and includes substantive financial data and analysis, not just an announcement or summary. Form 6-K is used by foreign private issuers to report current financial and operational information between annual reports (20-F). Given the detailed quarterly and annual financial results and management commentary, this filing fits the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K or 20-F), nor is it a simple announcement or certification. Therefore, the appropriate classification is IR (Interim / Quarterly Report).
2011-01-28 English
SC TO-T Filing
M&A Activity Classification · 100% confidence The document is a Schedule TO filing with the SEC, which is a Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934. It relates to a tender offer by Novartis AG and its subsidiaries to purchase all outstanding shares of Genoptix, Inc. The document includes detailed information about the tender offer, terms of the transaction, identity of the offeror, and exhibits such as the Offer to Purchase and Letter of Transmittal. This type of filing is specifically related to merger and acquisition activity, particularly tender offers. Therefore, the document fits the category of M&A Activity (TAR). The document length is substantial (over 14,000 characters) and contains detailed transaction information, not just an announcement or summary, so it is not a report publication announcement or regulatory filing. Hence, the correct classification is TAR with high confidence.
2011-01-28 English
PRIMARY DOCUMENT
Director's Dealing
2011-01-27 English
20-F
Annual Report FY 2010
2011-01-27 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content includes detailed financial results for the full year 2010 and the fourth quarter of 2010, including net sales, operating income, net income, EPS, and other financial metrics. It also discusses business highlights, product approvals, pipeline updates, and strategic initiatives. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F, often including interim or quarterly financial results. Given the detailed financial data and analysis for a period shorter than a full fiscal year (quarterly and annual highlights), and the nature of the Form 6-K as a report of foreign private issuers, this filing aligns best with an Interim / Quarterly Report (IR) classification rather than an Annual Report (10-K) or a simple announcement. Therefore, the appropriate classification is IR with high confidence.
2011-01-27 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.